

PATIENT AND PHYSICIAN INFORMATION

Patient: Olson, MaryAnn H.
Sex: Female **Date of Birth:** 03/15/1952
Medical Record/Patient Number: SO967221
Date of Surgery: 12/14/2010
Tissue Form: Unstained Slides; Stage II Colon Cancer
Date of Sample Receipt: 12/15/2010

Requisition Number: S039LGY
Date of Report: 3/17/2011
Ordering Facility: Southwest Oncology, In
Ordering Physician: Samuel Jackson
Pathologist: James Anderson
Additional Recipient: Jonathan Wayne

ONCODEFENDER™ - CRC ASSAY


OncoDefender™ -CRC measures expression levels of 10 genes (5 tumor-specific genes plus 5 reference genes) from Stage I/II colon carcinoma or Stage I rectal carcinoma tissues using a standard qRT-PCR process. The relative risk of colorectal cancer recurrence is determined based on the expression levels of all 10 genes and the interrelationships of the 5 tumor-specific genes.

RESULT

LOW RISK **HIGH RISK** of colorectal cancer recurrence within 3 years.

INTERPRETATION OF RESULT

Risk levels reflect external validation study data presented at the 2011 ASCO/ASTRO/SSO Gastrointestinal Cancers Symposium. The accompanying figure illustrates that 73% of individuals measuring 'Low Risk' (top red line) remained recurrence-free at 36 months (3 years), compared to 49% of those measuring 'High Risk' (bottom blue line) remaining recurrence-free over the same 3-year period. On average, those patients in the High Risk group are more than twice as likely to recur within 3 years after initial complete surgical resection as those in the Low Risk group (Hazard ratio 2.06; 95% CI: 1.10-3.86; p=0.020).



Analyst: _____ Date: _____

Result Reviewed and Accepted by: _____ Date: _____
 Laboratory Director

The performance characteristics of this test were validated by Everist Genomics. U.S. Food and Drug Administration (FDA) has not approved or cleared this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Everist Genomics is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.